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ABSTRACT
Background. The safety and efficacy of combination 
tablets of metformin plus sulfonylurea or plus dipep-
tidyl peptidase-4 inhibitors have not been studied 
previously. This study aimed to compare the efficacy 
and safety of Gliconorm versus Sitavia plus among pa-
tients with type 2 diabetes mellitus who fast Ramadan. 
Methods. This was an open-label study conducted from 
1 May 2018 till 1 July 2018. People with type 2 diabetes 
mellitus who were drug-naïve or on metformin only, 
with HbA1c < 10 % were included. The participants 
were divided into two groups. The first g roup was 
given Gliconorm (glibenclamide 5 mg + metformin 
1000 mg), while the second group was given Sitavia 
plus (sitagliptin 50 mg + metformin 1000 mg) imme-
diately after Iftar. Glycated hemoglobin (HbA1c) was 
measured before and after Ramadan. Several home 
recordings of blood glucose were collected. In addi-
tion, patients were asked to report any hypoglycemic 
or severe hyperglycemic episodes. 
Results. A total of 34 participants (18 women) (19 in the 
first group and 15 in the second group) were involved 
the study. The mean age was 49.6 ± 9.3 years. HbA1c re-
duced from 8.7 % (72 mmol/mol) to 7.6 % (60 mmol/mol) 
and from 8.7% (72 mmol/mol) to 7.7 % (61 mmol/mol) 
in the first and second group, respectively (p < 0.0001).  
Only one patient in the first group experienced one 
episode of hypoglycemia and hyperglycemia. 
Conclusion. Both medications seem to be safe and 
effective during Ramadan fasting. (Clin Diabetol 
2021; 10)
Key words: Ramadan; sulfonylurea; dipeptidyl 
peptidase-4 inhibitors; fasting; hypoglycemia
Introduction
Ramadan Fasting is one of the five pillars of Islam. 
All healthy adult Muslims should fast the month, which 
includes refraining from eating, drinking and sexual 
activity from dawn to sunset [1]. Despite the fact that 
Islamic rules have exempted sick people such as those 
with diabetes from fasting, many choose to fast [2]. 
As Ramadan`s timing is based on the lunar calendar, 
the length of Ramadan`s day differs depending on 
the season. For instance, in some parts of the world 
people may fast for 20 hours a day [1]. In our locality, 
fasting during May–June (the time of our study) lasts 
about 14 hours. This represents a great challenge for 
diabetic patients who practice fasting and place them 
at increased risk of complications. Of these, the most 
important are hypoglycemia and dehydration during 
fasting hours and hyperglycemia post Iftar (the main 
meal after breaking the fast which coincides with sun-
set) [3]. Therefore, for people with diabetes who wish to 
fast Ramadan, a relatively safe and effective treatment 
should be chosen. Many previous studies tested the ef-
ficacy and safety of different antidiabetic medications 
[4–22]. Based on these studies, several guidelines have 
been published [1, 23]. Most of the current guidelines 
recommend against the use of second generation 
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sulfonylurea (SU) during Ramadan due to their hypo-
glycemic potential [1]. On the other hand, dipeptidyl 
peptidase-4 inhibitors (DPP-4i) are considered generally 
safe with minimum side effects especially in terms of 
hypoglycemia [4, 5, 7, 11, 15, 16, 19, 22]. Few studies 
compared the efficacy and safety of SU versus DPP4i 
in head-to-head trials [4, 7, 15, 19]. However, to the 
best of our knowledge no study has been conducted 
on the use of both families in combination tablet in 
Ramadan so far. 
The combination of two drugs in one tablet might 
affect the pharmacodynamics and/or pharmacokinetics 
of drugs. This study aimed to compare the efficacy and 
safety of Gliconorm (glibenclamide plus metformin) 
versus Sitavia plus (sitagliptin plus metformin) among 
diabetic patients who fast Ramadan.
Material and methods
Study design
This was an open-label non-randomized study 
conducted at Faiha Specialized Diabetes, Endocrine and 
Metabolism Center, Basra, Iraq from 1 May 2018 till 
1 July 2018. People with type 2 diabetes mellitus (T2D) 
(age ≥ 18 years) who were drug-naïve or on metformin 
only, with HbA1c < 10 % and intended to fast Ramadan 
were included in the study. On the other hand, those 
with type 1 diabetes mellitus, those on insulin or oral 
antidiabetic medication except metformin, pregnant 
women, those with gestational diabetes, history of dia-
betic ketoacidosis, liver disease, heart failure (New York 
Heart Association class III or IV), chronic kidney disease 
(estimated glomerular filtration rate by Cockroft-Gault 
< 45 mL/min/1.73 m2), those who do not wish to fast 
or had a contraindication for the use of DPP4i were 
excluded from the study. The eligible participants were 
divided into two groups in a 1:1 ratio. The first group 
was given a combination tablet of glibenclamide 5 mg 
+ metformin 1000 mg (Gliconorm, Abiogen pharma, 
Italy), while the second group was given sitagliptin 
50 mg + metformin 1000 mg (Sitavia plus, Pioneer 
pharma, Iraq) immediately after Iftar. The same start-
ing doses of medications were kept during Ramadan 
without any change. All the participants were given an 
individualized meal plan by a dietitian based on their 
basal metabolic rate. Furthermore, they were instructed 
to continue their usual daily activity and avoid exercise. 
At the first visit (at least a month before Ramadan), the 
following data were gathered: age, gender and dura-
tion of diabetes in years. Besides that, body weight and 
body mass index (BMI) were recorded. In addition, gly-
cated hemoglobin (HbA1c) and fasting plasma glucose 
(FPG) were measured. In addition, all the participants 
were asked to start their designated treatment at the 
first visit. During the month of Ramadan, the patients 
were asked to record several self-monitored blood 
glucose (SMBG) readings before Iftar and 2 hours 
postprandial by a glucometer (Accu-Check Aviva Plus, 
Roche Diabetes Care Inc., Basel, Switzerland). Addition-
ally, patients were asked to report any hypoglycemic 
(SMBG < 70 mg/dL) or severe hyperglycemic (SMBG 
> 300 mg/dL) episodes as well as the number of days 
they broke their fast.
Laboratory measurements
Fasting plasma glucose was measured by the hexoki-
nase method (Cobas Integra C111, Roche Diagnostics, 
Basel, Switzerland). HbA1c was measured by Cation-
exchange high-performance liquid chromatography 
method (Bio-Rad D-10, Bio-Rad Laboratories, CA, USA).
Outcome measures
The primary endpoint of this study was the mean 
difference in HbA1c before and after Ramadan. While 
the secondary endpoints included mean change in 
fasting and random blood glucose, episodes of any 
hypoglycemia (defined as SMBG < 70 mg/dL), severe 
hypoglycemia (requiring assistance by another person), 
severe hyperglycemia (defined as SMBG > 300 mg/dL) 
and any hospital admission for diabetes-related emer-
gencies. The participants were reassessed after the end 
of Ramadan within a time window of 10 days where 
body weight, BMI, HbA1c and FPG were measured 
again. In addition, all SMBG readings were reviewed 
and recorded.
Statistical analysis
Descriptive data are presented as the mean ± SD 
for normally distributed data or, when distribution 
was skewed, as the median and interquartile range. 
Changes in the means of HbA1c values, FPG, pre- and 
post-Iftar glucose, and BMI before and after Rama-
dan were analyzed by paired Student’s t test. All data 
analyses were performed with IBM SPSS for Windows 
25.0 (SPSS Inc., Chicago, IL, USA). P values < 0.05 were 
considered significant.
Ethical considerations
This study was designed and conducted in accord-
ance with the principles stated by the Declaration of 
Helsinki of 1975, as revised in 2013. The study was 
reviewed and approved by the Scientific Committee of 
Basrah Health Directorate on the 15th of April 2018 with 
the code (APR/203). An informed consent was obtained 
from all human adult participants. This research did not 
receive any specific grant from funding agencies in the 
public, commercial, or not-for-profit sectors.




At the screening visit, 100 participants were re-
cruited and divided equally into the two arms. However, 
ultimately a total of 34 participants (18 women) (19 in 
the first group and 15 in the second group) completed 
the study (Figure 1). 
The mean age was 49.6 ± 9.3 years with a mean 
duration of diabetes of 2.9 ± 0.5 years. The mean BMI 
was 32.0 ± 1.0 kg/m2 (Table 1). 
Glycemic control
There was a significant reduction in HbA1c from 8.7% 
(72 mmol/mol) to 7.6 % (60 mmol/mol) and from 
8.7% (72 mmol/mol) to 7.7 % (61 mmol/mol) in the 
first and second groups, respectively (p < 0.0001), as 
shown in Figure 2. 
A total of 268 SMBG readings were recorded by 
the participants. The mean fasting and postprandial 
glucose values were 123 mg/dL and 193 mg/dL in the 
first group and 130 mg/dl and 177 mg/dL in the second 
group, respectively (p value between groups 0.4 for 
fasting and 0.08 for postprandial). 
Adverse events
Only one patient in the first group experienced one 
episode of mild hypoglycemia that did not necessitate 
breaking the fast and one episode of severe hypergly-
Table 1. Basic characteristics of the participants
Variable Gliconorm Sitavia plus Total
Age [years] (mean ± SD) 51 ± 10 47 ± 8 49.6 ± 9.3
Gender [n]
Males 12 4 16
Females 7 11 18
Duration of diabetes [years] (median ± SE) 3.3 ± 0.7 1.8 ± 0.5 2.9 ± 0.5
BMI [kg/m2] (mean ± SD) 32.0 ± 1.0 33.0 ± 2.0 32.0 ± 1.0
Entry HbA1c [%] (mean ± SD) [mmol/mol] 8.7 ± 1.4 (72) 8.7 ± 1.4 (72) 8.7 ± 1.4 (72) 
BMI — body mass index; HbA1c — glycated hemoglobin
Screened, n = 2340
Excluded, n = 2240
Type 1 diabetes mellitus, n = 112
On insulin, n = 640
On oral antidiabetic except metformin, n = 892
Pregnant or gestational diabetes, n = 40
History of DKA, n = 36 
Heart failure, n = 28
Chronic kidney disease, n = 112
Do not wish to fast, n = 380
Recuited, n = 100
Gliconorm, n = 50 Sitavia plus, n = 50
Discontinued, n = 31
Reasons
• Lost to follow-up, n = 15
• Did not comply, n = 9
• Came after 10 days, n = 7
Discontinued, n = 35
Reasons
• Lost to follow up, n= 17
• Did not comply, n=12
• Came after 10 days, n=6
Completed, n = 19 Completed, n = 15
Figure 1. Study flow chart
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cemia. None of the participants reported admission 
to hospital for diabetes-related complications. There 
was no change in BMI in both groups at the end of 
Ramadan. All the participants fasted the whole month.
Discussion
This study evaluated the efficacy and safety of 
combination therapy (SU + metformin versus DPP4i 
+ metformin) in Muslim patients with T2D during 
Ramadan. This study shows a significant reduction 
in HbA1c before and after Ramadan in both arms. 
However, there was no significant difference in the 
efficacy of both tested drugs (Gliconorm and Sitavia 
plus) in reducing HbA1c. In terms of glycemic control, 
the results of previous studies on glibenclamide are 
contradictory. One study documented a reduction in 
HbA1c by 0.9% [19]; two studies revealed no change in 
HbA1c
 [5, 18] and a single study showed an increment 
from baseline by 0.4% [10]. Similarly, previous studies 
on DPP4i showed either no change in HbA1c [11, 15], 
or a minimal reduction by 0.2% and 0.4% [5, 16]. Our 
study is the first one that documented the larger and 
significant reduction in HbA1c in people who used 
glibenclamide and sitagliptin in combination with met-
formin. This might be explained by two factors: First, 
we used a combination tablet that might have changed 
the pharmacodynamics and/or the pharmacokinetics 
of the drug and patient compliance with the therapy. 
Second, the majority of the participants in our study 
were newly diagnosed as is evident by the short mean 
duration of diabetes (2.9 ± 0.5 years). We observed 
a nonsignificant difference in the means of both fasting 
and postprandial glucose in both groups. However, we 
have not compared the changes in the mean fasting 
and postprandial glucose readings in the same group 
before and after Ramadan. Only one participant in 
the Gliconorm arm reported a single episode of mild 
hypoglycemia and a single episode of severe hypergly-
cemia. However, these 2 episodes passed uneventfully 
and the index participant completed his fast safely. 
Several observational and randomized controlled tri-
als (RCTs) showed that the use of second generation 
SUs such as glibenclamide during Ramadan carries 
a high risk of hypoglycemia with an incidence ranging 
from 8–25% [4, 5, 7, 10, 18]. Nevertheless, none of 
these studies except one done by Belkhadir et al. com-
pared the incidence of hypoglycemia before and after 
Ramadan [10]. Therefore, the hypoglycemia incidence 
might be related to the drug itself rather than to its 
use in Ramadan. Belkhadir et al. conducted a RCT on 
glibenclamide and found a lower rate of hypoglycemic 
events unexpectedly during Ramadan. The same study 
has documented the lower ever reported incidence of 
hypoglycemia in the glibenclamide group [10]. This 
might be explained by the fact that the baseline HbA1c 
in that study was high (13.7%), which makes severe 
hypoglycemia very unlikely. 
The rate of hypoglycemic episodes in Belkhadir 
study was 10/183 which is similar to our study (1/19) 
[10]. Given the small sample size in our study, we may 
have underestimated the rate of hypoglycemia among 
Gliconorm arm. There is a wide variation in the reported 
incidence of hypoglycemia among patients using DPP4i 
in previous studies ranging from 0–34.2% [4, 5, 7, 11, 
13, 15, 16, 19, 22]. The highest hypoglycemia rate 
was documented by Halimi et al.’s study which was an 
observational study. The low baseline HbA1c and the 
prolong fasting hours (16 hours) might explain the high 
reported rate in that study [13]. Given the observational 
design of their study, the possibility of over-reporting 
should be considered. None of the participants in our 
study reported hypoglycemia in the Sitavia plus arm. 
This is in line with two other studies where the rate was 
zero as well [15, 22]. However, the small sample size in 
our study might underpower it to detect the real rate 
of hypoglycemia.
Ramadan fasting represents a great challenge for 
people with T2D due to two potential complications. 
First, severe hypoglycemia mainly during the last two 
hours of daytime especially if the patient is using anti-
diabetic drug with hypoglycemic potential. Second, 
severe hyperglycemia immediately after breaking the 
fast by Iftar meal as this meal is usually rich in carbo-
hydrates and considered to be like a feast rather than 
a meal.24 Therefore, people with T2D need a safe and 
effective medication during Ramadan. A safe medica-
tion usually means it has low hypoglycemia risk and 
effective medication means it reduces HbA1c effectively 
Figure 2. Change in HbA1c in both groups before and after 
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during the month of Ramadan. According to our re-
sults, both studied medications demonstrated safety 
and effectiveness.
In our study, we have not demonstrated any signifi-
cant change in body weight and consequently in BMI 
which is in line with other studies [10, 13, 15, 16, 25]. 
In contrast, other studies demonstrated a statistically 
significant weight loss in DPP4i more than in SU [5, 
19, 22]. Only one study showed an increment in body 
weight from baseline in both DPP4i and SU groups and 
it was statistically significant in the latter [11]. Gener-
ally, previous observations in non-fasting times have 
demonstrated a weight neutral effect of DPP4i and 
weight gain effect of SU. During Ramadan, the total 
calorie intake is generally reduced (fasting people are 
consuming two meals only). This might explain the 
weight neutral phenomena of both treatment groups 
that we have observed in our study. Besides that, the 
addition of metformin might have minimized the 
weight gaining effect of SU.
In this study, patients in the Gliconorm arm were 
older than those in the Sitavia plus arm (51 years and 
47 years, respectively. However, this difference was 
not large enough to affect the results. Furthermore, 
a previous study has shown there is no effect for age 
difference on glycemic control of patients [26]. 
Males predominated in the Gliconorm arm while 
in the Sitavia plus arm, females were the most pre-
dominant. The effect of gender on glycemic control 
is a matter of debate. Some studies demonstrated an 
effect with females have worse control [27]. On the 
other hand, other studies demonstrated no difference 
[28]. There are several limitations to this study that 
warrants consideration. First, the small sample size 
might have underpowered the ability of the study to 
estimate the secondary endpoints (incidence of hypo-
glycemic and hyperglycemic episodes during Ramadan). 
Second, it has been conducted in a single center. Third, 
the high dropout rate which is mainly attributed to 
failure of majority of the participants to show up at 
the follow-up visit within the pre-specified time limit 
after Ramadan (10 days). This time window was set as 
such to minimize the effect of excessive consumption 
of carbohydrates that usually follows Ramadan fasting 
during Eid Festival. Finally, given the short period of 
fasting (a month), the use of fructosamine might have 
been more robust indicator of glycemic control than 
HbA1c. However, most of the previous studies that were 
conducted during Ramadan utilized the latter as a sur-
rogate of glycemic control. On the other hand, there 
are strength points that deserve to be mentioned. First, 
the prospective design of the study has allowed a sys-
tematic and detailed follow up and outcome definition. 
Second, the participants were instructed to report and 
record blood sugar at the time of hypoglycemia and 
several times after breaking the fast by two hours to 
study hyperglycemia. Finally, to limit the confounding 
effect of dietary intake and exercise, all the participants 
were asked to follow an individualized meal plan and 
to avoid exercise during Ramadan.
Conclusions
It seems that the use of both drugs, Gliconorm 
and Sitavia plus, is effective and safe during the month 
of Ramadan. Proper patient education plays a major 
role in minimizing the anticipated side effects of most 
medications during fasting. The use of combination 
tablets during Ramadan has a promising beneficial 
outcome in terms of improved patient compliance 
and convenience as well as minimizing side effects. 
Larger RCTs are required to build a robust conclusion 
on the safety and efficacy of combination tablets dur-
ing Ramadan fasting.
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